HGEN - Humanigen and Ajinomoto expand manufacturing agreement for lenzilumab development

Humanigen ([[HGEN]] +0.5%) and Ajinomoto Bio-Pharma Services announce that the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, a Phase 3 treatment option in development for patients hospitalized with COVID-19.Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazil and preparing for a potential COVID-19 Emergency Use Authorization ((EUA)) for lenzilumab.Aji Bio-Pharma will assume a key role in simplifying the supply chain efforts by providing drug product aseptic fill finish services at its San Diego facility to support continued clinical trial efforts, Humanigen said.The update comes days after Humanigen and Emergent BioSolutions ([[EBS]] -1.4%) entered into a contract development and manufacturing services agreement to accelerate the drug product manufacturing of lenzilumab, to prevent and treat an immune hyper-response called "cytokine storm".

For further details see:

Humanigen and Ajinomoto expand manufacturing agreement for lenzilumab development